Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Novartis Notes

All regions grew in the second quarter. Sales in the US were USD 965 million (+5% cc), driven by a strong base business performance and despite a lower level of launches compared to a strong prioryear quarter, which included the launch and shipping of initial trade inventories of Glatopa. Sales in Western Europe were USD 726 million (+3% cc), with strong growth in France and slight growth in Germany. In emerging markets, Latin America sales grew 9% (cc) to USD 92 million, driven by double-digit growth in Brazil, while Middle East and Africa sales grew 7% (cc). Central and Eastern Europe sales were USD 283 million (+4% cc), despite the continued impact of the negative macroeconomic environment. Asia Pacific sales grew 3% (cc) to USD 204 million, with growth impacted by the commercial exit of low-margin businesses.


Global sales of Biopharmaceuticals (including biosimilars, biopharmaceutical contract manufacturing and Glatopa) grew 11% (cc) to USD 249 million, despite lapping the Glatopa launch in the prior-year quarter. Sandoz continued to see strong growth for its three in-market biosimilars – Omnitrope (somatropin), Binocrit (epoetin alfa) and Zarzio (filgrastim) – and strong patient uptake for the recently launched Glatopa and Zarxio in the US. Anti-Infectives franchise sales (partner label and finished dosage form sales) were USD 324 million (-3% cc), reflecting the discontinuation of low-margin products.